103_CD Alliance_NNP UniChem_NNP Plc_NNP 42_CD ACQUISITIONS_NNP CONTINUED_VBD Purchase_NN of_IN businesses_NNS continued_VBD Retail_NNP Book_NNP Provisional_NNP value_NN at_IN Fair_NNP value_NN fair_JJ value_NN at_IN acquisition_NN adjustments_NNS acquisition_NN Assets_NNS acquired_VBN at_IN book_NN and_CC provisional_JJ fair_JJ value_NN million_CD million_CD million_CD Intangible_JJ assets_NNS retail_JJ pharmacy_NN licences_VBZ 24.7_CD 69.2_CD 93.9_CD Property_NN ,_, plant_NN and_CC equipment_NN 6.7_CD 0.2_CD 6.5_CD Inventories_NNS 11.2_CD 0.5_CD 10.7_CD Trade_NNP and_CC other_JJ receivables_NN 9.2_CD 0.2_CD 9.4_CD Borrowings_NNS bank_NN overdrafts_NNS 2.5_CD 2.5_CD bank_NN loans_NNS 2.5_CD 2.5_CD Trade_NNP and_CC other_JJ payables_NNS 10.7_CD 10.7_CD Current_JJ corporate_JJ tax_NN liabilities_NNS 3.3_CD 0.1_CD 3.4_CD Deferred_JJ tax_NN liabilities_NNS 20.6_CD 20.6_CD Net_JJ assets_NNS acquired_VBN 32.8_CD 48.0_CD 80.8_CD Consideration_NNP paid_VBD million_CD Cash_NNP 117.3_CD Deferred_JJ consideration_NN movement_NN 0.3_CD 117.0_CD Purchased_VBN goodwill_NN 36.2_CD Retail_NNP acquisitions_NNS comprised_VBD the_DT acquisition_NN of_IN 83_CD pharmacies_NNS in_IN the_DT UK_NNP ,_, Norway_NNP and_CC The_DT Netherlands_NNP ._.
43_CD DISPOSALS_NNP Disposal_NNP of_IN businesses_NNS During_IN the_DT year_NN the_DT Group_NNP disposed_VBD of_IN 51_CD %_NN of_IN its_PRP$ interest_NN in_IN Alliance_NNP UniChem_NNP Farmacutica_NNP A._NN G._NNP its_PRP$ entire_JJ interest_NN in_IN Elvetec_NNP in_IN France_NNP and_CC a_DT number_NN of_IN other_JJ minor_JJ interests_NNS ._.
The_DT proceeds_NNS received_VBD for_IN these_DT transactions_NNS were_VBD 32.5_CD million_CD ._.
Within_IN the_DT balance_NN sheets_NNS of_IN the_DT businesses_NNS disposed_VBN were_VBD net_JJ overdrafts_NNS of_IN 66.2_CD million_CD ._.
In_IN addition_NN ,_, the_DT Group_NNP received_VBD deferred_VBN consideration_NN of_IN 12.0_CD million_CD arising_VBG from_IN the_DT disposal_NN of_IN non-core_JJ UK_NNP businesses_NNS in_IN 2004_CD ._.
Disposal_NN of_IN investments_NNS in_IN associates_NNS As_IN described_VBN in_IN note_NN 42_CD ,_, during_IN the_DT year_NN the_DT Group_NNP restructured_VBD its_PRP$ relationship_NN with_IN Galenica_NNP A._NNP G._NNP ._.
The_DT transaction_NN was_VBD settled_VBN on_IN a_DT net_JJ basis_NN and_CC resulted_VBD in_IN a_DT net_JJ cash_NN inflow_NN to_TO the_DT Group_NNP of_IN 15.7_CD million_CD ._.
This_DT comprised_VBN 8.6_CD million_CD of_IN net_JJ proceeds_NNS ,_, 41.4_CD million_CD of_IN associate_JJ loans_NNS being_VBG repaid_VBN and_CC ,_, in_IN respect_NN of_IN the_DT acquired_VBN companies_NNS ,_, 2.0_CD million_CD of_IN net_JJ cash_NN and_CC 36.3_CD million_CD of_IN borrowings_NNS were_VBD held_VBN in_IN the_DT acquired_VBN balance_NN sheets_NNS ._.
In_IN addition_NN ,_, the_DT Group_NNP disposed_VBD of_IN a_DT minor_JJ associated_VBN undertaking_NN for_IN disposal_NN proceeds_NNS of_IN 0.1_CD million_CD ._.
Disposal_NN of_IN available-for-sale_JJ investments_NNS During_IN the_DT first_JJ half_NN of_IN the_DT year_NN ,_, the_DT Group_NNP disposed_VBD of_IN its_PRP$ investment_NN in_IN Sanacorp_NNP Pharmahandel_NNP A._NN G._NNP ._.
44_CD SHARE-BASED_JJ PAYMENTS_NNS The_DT Group_NNP issues_NNS equity_NN settled_VBD ,_, share-based_JJ payments_NNS to_TO certain_JJ employees_NNS ._.
Equity_NNP settled_VBD share-based_JJ payments_NNS are_VBP measured_VBN at_IN fair_JJ value_NN at_IN the_DT date_NN of_IN grant_NN ._.
The_DT fair_JJ value_NN determined_VBN at_IN the_DT grant_NN date_NN of_IN the_DT equity_NN settled_VBD ,_, share-based_JJ payments_NNS is_VBZ expensed_VBN on_IN a_DT straight-line_JJ basis_NN over_IN the_DT vesting_JJ period_NN ,_, based_VBN on_IN the_DT Groups_NNS estimate_NN of_IN shares_NNS that_WDT will_MD eventually_RB vest_NN ._.
Fair_NNP value_NN is_VBZ measured_VBN by_IN use_NN of_IN an_DT actuarial_JJ binomial_JJ model_NN ._.
The_DT model_NN includes_VBZ adjustments_NNS ,_, based_VBN on_IN managements_NNS best_JJS estimate_NN ,_, for_IN the_DT effects_NNS of_IN exercise_NN restrictions_NNS ,_, behavioural_JJ considerations_NNS and_CC expected_VBN dividend_NN payments_NNS ._.
The_DT option_NN life_NN is_VBZ derived_VBN by_IN the_DT model_NN based_VBN on_IN these_DT assumptions_NNS and_CC the_DT other_JJ assumptions_NNS identified_VBN below_IN ._.
The_DT total_JJ expense_NN included_VBD within_IN profit_NN from_IN operations_NNS in_IN respect_NN of_IN share-based_JJ payments_NNS was_VBD 5.3_CD million_CD 2004_CD 2.2_CD million_CD ._.
